22-minute walk benefits, Nigeria's HPV vaccine push, China's oil refining cap, and GSK's promising RSV vaccine

Today ChatGPT read 1055 top news stories. After removing previously covered events, there are 4 articles with a significance score over 7.

[7.2] Brisk walking for 22 minutes daily counters negative effects of sitting. — The Guardian

A study published in the British Journal of Sports Medicine suggests that going for a brisk walk for just 22 minutes once a day can offset the negative health effects of sitting too much. Sedentary lifestyles are a leading cause of ill health worldwide, but moderate-to-vigorous physical activity can eliminate the increased risk from being sedentary. The study found that every minute of higher moderate-to-vigorous physical activity showed a lower risk of death, and doing 22 minutes or more per day eliminated the higher risk of death from sedentary time.

[7.2] Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer. — UN News

Cervical cancer is the third most common cancer and the second leading cause of cancer deaths among women aged 15 to 44 in Nigeria. In 2020, there were 12,000 new cases and 8,000 deaths from cervical cancer in the country. To combat this, Nigeria has launched a nationwide vaccination campaign, targeting 7.7 million girls aged nine to 14, with the goal of preventing the infection of HPV types that cause at least 70% of cervical cancers. The vaccine will be provided for free by the Federal Ministry of Health, with support from Gavi, UNICEF, WHO, and other partners.

[7.0] China to cap crude oil refining capacity to reduce emissions. — Reuters

China's state planning agency, the National Development and Reform Commission (NDRC), has confirmed that it will cap its crude oil refining capacity at 1 billion metric tons by 2025 in order to streamline the sector and reduce carbon emissions. China surpassed the United States as the world's largest oil processor in 2022, with a refining capacity of 920 million tonnes per year. The NDRC will limit new refining capacity, promote the upgrading and optimization of refineries, and accelerate the closure of small and outdated plants.

[7.0] GSK's RSV vaccine shows positive results in late-stage trial. — Reuters

GSK has announced that its vaccine for respiratory syncytial virus (RSV), called Arexvy, has shown positive preliminary results in a late-stage trial. The vaccine met its primary goal of eliciting an immune response in adults aged 50 to 59 who are at an increased risk of catching the virus due to certain underlying medical conditions. RSV is a leading cause of pneumonia in toddlers and the elderly, and the vaccine has already been approved in several countries to protect adults aged 60 and older.

Want to read more?

See additional news on newsminimalist.com.

Thanks for reading us and see you tomorrow,

Vadim